Therapy-specific authorization and prescriber requirements

Therapy-specific authorizations and prescriber requirements: Many disease-modifying therapies (DMTs) and specialty agents for multiple sclerosis require prescribers to be neurologists or to consult with a neurologist. Precertification (prior authorization) is required for MS medications in applicable plan designs; providers should use Aetna's precertification phone (866-752-7021) or fax (888-267-3277) and submit the Statement of Medical Necessity (SMN) when requested. Site-of-care policies may apply for certain infused specialty drugs (e.g., alemtuzumab/Lemtrada, natalizumab/Tysabri, ocrelizumab/Ocrevus, immune globulin, ublituximab-xiiy/Briumvi) and authorization requests should document enrollment in required REMS or restricted distribution programs when applicable.

• Prescriber specialties: many agents must be prescribed by or in consultation with a neurologist (e.g., Lemtrada, Ocrevus, Briumvi).
• Precertification contact: phone (866-752-7021); fax (888-267-3277); use SMN forms via Specialty Pharmacy Precertification.
• Site-of-care utilization management may apply for select infused therapies.

Prior authorization for DMTs

Prior authorization for DMTs: HCPCS/J-codes and other injectable or infused specialty agents (listed in the CPT/HCPCS section) require authorization when selection criteria must be met. Include exact CPT, HCPCS and ICD-10 codes on submissions and provide supporting documentation of diagnosis, prior therapies, MRI findings, EDSS scores, and clinical course as applicable.

• Include HCPCS J2329 (ublituximab-xiiy), J2350 (ocrelizumab), J0202 (alemtuzumab), J9293 (mitoxantrone) when applicable and supply supporting documentation.
• Document failure/intolerance to prior DMTs per policy definitions (relapses, MRI lesion progression, worsening EDSS).

Authorization for Briumvi

Authorization for Briumvi (ublituximab): Briumvi is a specialty, HCPCS-coded infused DMT that requires prior authorization/precertification in applicable plan designs. Authorization requests should document neurologist prescribing (or consultation), indication (relapsing forms of MS or CIS), prior therapy history if applicable, and adherence to pre-infusion screening (hepatitis B and quantitative immunoglobulins) and premedication per label. Site-of-care rules may apply.

• Pre-infusion screening required: hepatitis B testing and quantitative serum immunoglobulin levels (per label).
• Document neurologist involvement, indication, and prior DMT trials or contraindications/intolerance if invoking brand-step exceptions.

Venoplasty prior authorization expectation and regulatory risk

Venoplasty / CCSVI procedures: Balloon venoplasty/angioplasty for chronic cerebrospinal venous insufficiency (CCSVI) is unsupported by high-quality evidence and has regulatory safety concerns. Prior authorization expectations: such procedures would be subject to denial or require extensive documentation of investigational device approvals and trial enrollment; indicate that devices are not FDA-approved for CCSVI and serious adverse events have been reported.

• CPT code 35476 (transluminal balloon angioplasty, percutaneous; venous) is listed in coding section — expect scrutiny and likely noncoverage for CCSVI treatment.
• Documented randomized/sham-controlled trial evidence and investigational device exemption (IDE)/FDA approvals must be provided to consider coverage; absence of such evidence supports denial.

IVIG prior authorization cross-reference

IVIG prior authorization cross-reference: Use CPB 0206 (Parenteral Immunoglobulins) for prior authorization rules and criteria when requesting IVIG/immune globulin for MS-related indications; follow site-of-care and specialty infusion authorization processes as applicable.

• Refer to CPB 0206 for IVIG clinical criteria, documentation, and precertification requirements.
• Site-of-care policy may apply for immune globulin infusions.

Prior authorization recommended for investigational MS biologic therapies

Prior authorization recommended for investigational MS biologic therapies and other experimental procedures: Mesenchymal stem cell therapies, antigen-specific peptide therapies, novel T-cell approaches, and other items listed as experimental/investigational require prior authorization with robust trial evidence; absent high-quality data these services are considered investigational and may be denied.

• MSC therapy: provide randomized controlled trial evidence and safety data; otherwise likely investigational denial.
• Antigen-specific peptide therapy (e.g., Xemys): phase I safety data alone is insufficient — document trial phase, outcomes, and safety monitoring when requesting coverage.

Serum Nf monitoring interval

Serum neurofilament (sNfL) monitoring interval: When used in monitoring disease activity, evidence cited suggests a 3-month interval between blood tests for serum neurofilament light (sNfL) to detect new disease activity; however, routine use is currently considered investigational pending further validation and reproducibility.

• If sNfL is submitted as part of an authorization or monitoring plan, document clinical intent, baseline values, and plan for 3-month interval re-checks when claiming monitoring of disease activity.
• Recognize limitations: sNfL remains a research/adjunct marker and coverage may be denied without clear clinical necessity.

No prior authorization specified in some evidence sections

No prior authorization specified in some evidence sections: Several background and bibliographic sections (e.g., literature summaries, appendices, references) do not establish payer-specific prior authorization or coverage rules; providers must rely on the policy clinical criteria and coding sections when preparing authorization requests.

• Evidence summaries do not replace operational authorization criteria — submit clinical documentation that aligns with policy criteria.
• When no explicit authorization guidance is present, include detailed clinical notes, imaging, and prior therapy documentation to support medical necessity determinations.

Experimental / Investigational denials

Experimental / Investigational denials: Services and tests listed in the Experimental and Investigational section (including concomitant use of multiple DMTs, novel biomarkers, and unproven procedures) are considered investigational and are typically not covered. Authorization requests for these items should include high-quality clinical trial evidence to be considered.

• Concomitant use of listed DMTs is considered experimental/investigational — document justification and supporting evidence if requested.
• Neutralizing antibody assays and certain biomarker tests are considered investigational without established clinical utility.

REMS enrollment and restricted distribution

REMS enrollment and restricted distribution: Some agents (e.g., alemtuzumab/Lemtrada, dalfampridine/Ampyra) are available only through REMS or restricted distribution programs. Authorization will be contingent upon documentation of patient enrollment in the REMS, use of certified prescribers/facilities/pharmacies, and adherence to REMS monitoring requirements.

• Lemtrada is available only through the Lemtrada REMS — document REMS enrollment and certified prescriber/facility/pharmacy participation.
• Dalfampridine distribution via specialty pharmacy with REMS-related communication; document renal function and seizure risk counseling.

Mitoxantrone cardiac monitoring and cumulative dose

Mitoxantrone cardiac monitoring and cumulative dose requirements: Prior authorization and continuation of mitoxantrone require documentation of baseline and periodic quantitative LVEF assessment, avoidance if baseline LVEF is below the lower limit of normal, withholding further doses for significant LVEF reduction, and monitoring cumulative lifetime dose (do not exceed 140 mg/m2). Yearly LVEF evaluation after stopping therapy is recommended to monitor late cardiotoxicity.

• Document baseline LVEF and quantitative LVEF reassessments prior to each dose (use same methodology as baseline).
• Ensure cumulative mitoxantrone dose does not exceed 140 mg/m2 — include dosing history in authorization requests.

Ocrelizumab pre-treatment screening and counseling

Ocrelizumab (Ocrevus) contraindication — hepatitis B screening and counseling: Per product labeling, screen for hepatitis B infection prior to initiating Ocrevus and document counseling and appropriate pre-medication. Ocrevus is contraindicated in active hepatitis B; failure to document screening may lead to denial or delay of authorization.

• Document hepatitis B testing results prior to first dose and quantitative immunoglobulin levels as applicable.
• Include pre-medication plan (eg, methylprednisolone and antihistamine) and infusion monitoring arrangements in authorization requests.

Briumvi administration and monitoring

Briumvi administration and monitoring expectations: Briumvi must be administered as an intravenous infusion under supervision with access to medical support to manage infusion reactions. Pre-infusion screening (hepatitis B, quantitative immunoglobulins) and pre-medication with corticosteroid and antihistamine are required per label; document infusion setting and monitoring plan when requesting authorization.

• Document infusion facility/site, prescriber specialty (neurology), and readiness to manage severe infusion reactions.
• Include schedule of loading and maintenance infusions (first 150 mg, second 450 mg at 2 weeks, subsequent 450 mg at 24 weeks and every 24 weeks thereafter) when submitting for coverage.

Evidence documentation for CCSVI/venoplasty

Evidence documentation for CCSVI/venoplasty: When clinicians request coverage for venoplasty/angioplasty related to CCSVI, provide randomized, sham-controlled trial data and systematic review findings. The evidence base currently does not support clinical benefit and safety signals have been reported; include FDA IDE or device approval documentation if claiming investigational trial coverage.

• Submit RCT or high-quality systematic review evidence; absent such data, expect denial as experimental/investigational.
• Provide documentation of FDA investigational device exemptions or trial approvals for procedures performed under research protocols.

gMS®Pro EDSS Test — evidence gap

gMS®Pro EDSS Test — evidence gap: The gMS®Pro EDSS biomarker panel lacks sufficient evidence of clinical utility; requests for coverage should include high-quality validation studies demonstrating prediction of progression and impact on management. Without such evidence, coverage is unlikely.

• Provide prospective validation and clinical utility data to support coverage consideration.
• Include how test results would change management and expected patient benefit.

Documentation for antigen-specific peptide therapy

Documentation for antigen-specific peptide therapy: Early-phase safety data (eg, phase I Xemys studies) are hypothesis-generating. Authorization for use outside clinical trials requires robust evidence of efficacy and safety; include trial phase, outcomes, safety monitoring, and rationale when requesting coverage for investigational peptide therapies.

• Phase I open-label/ proof-of-concept results are insufficient for routine coverage — provide RCT data if available.
• Document prior-line therapy failures and rationale for off-label or compassionate use when applicable.

No documentation or prior authorization specified in reference sections

No documentation or prior authorization in reference sections: Bibliographic and reference lists, appendices (McDonald criteria, EDSS) and policy history do not themselves establish authorization criteria. Use these resources to support clinical rationale but submit the required clinical documentation aligned to the policy's clinical criteria for medical necessity determinations.

• Appendix tools (McDonald criteria, EDSS) may be used to document diagnosis and disability but are not substitutes for required authorization documentation.
• Policy history and references are informational — include primary clinical data in authorization packages.

Administrative / Documentation links

Administrative/Documentation links and policy operations: Providers should use Aetna's Clinical Policy Bulletin notes, definitions, and online resources to locate forms, submission instructions, and review history. Ensure claims and authorization submissions align with plan design, coverage rules, and the CPT/HCPCS/ICD-10 codes listed in the policy.

• Use online forms for SMN and specialty precertification; verify plan-specific requirements.
• Align claim coding with the policy's CPT/HCPCS/ICD-10 lists and include clinical documentation supporting each billed code.

Brand-step requirement for Briumvi and Lemtrada

Brand-step requirement for Briumvi and Lemtrada: Aetna designates Briumvi and Lemtrada as higher-cost agents; these may be considered medically necessary only after documented contraindication, intolerance, or inadequate response to lower-cost alternatives (eg, ocrelizumab and natalizumab) per the brand selection rationale. Provide prior therapy trial documentation or contraindication evidence when requesting these agents.

• Document adequate trials of Ocrevus and Tysabri (or documented contraindication/intolerance) before approval of Briumvi or Lemtrada under brand-selection policy.
• Define 'failure of an adequate trial' per policy (relapse frequency, MRI progression, or sustained EDSS worsening).

PLEX / Plasmapheresis as escalation after steroids

Plasma exchange (PLEX) as escalation after steroids: PLEX/plasmapheresis is considered medically necessary for acute, severe MS relapses refractory to high-dose glucocorticoids. Do not use PLEX for chronic or secondary progressive MS maintenance; expect coding/authorization to reflect acute indication and failure of steroid therapy.

• CPT 36514 (therapeutic apheresis) is covered when selection criteria are met; document steroid-refractory status and acute severe neurologic deficit.
• PLEX is not supported for chronic or secondary progressive MS maintenance therapy.

Cannabinoids — consider prior conventional therapy

Cannabinoids — consider prior conventional therapy: Medicinal cannabinoids for symptom control (pain, spasticity, bladder dysfunction) have limited evidence; consider them after conventional therapies have been tried and document prior symptomatic treatment attempts. Coverage may be limited and require demonstration of prior conventional therapy failure.

• Document prior trials of standard symptomatic treatments before considering cannabinoids.
• Supply RCT evidence and patient-specific functional outcome data when requesting coverage for cannabinoids.

Step therapy / sequencing considerations

No step therapy policies or sequencing requirements specified in the evidence excerpts: While the policy outlines clinical sequencing for certain agents (for example, Lemtrada reserved after inadequate response to ≥2 prior DMTs), in many background sections no formal step therapy program is described. Providers should follow the explicit clinical criteria and brand-selection statements when documenting treatment history; absence of a formal step policy in a background section does not obviate the need to document prior therapies where the policy requires it.

• Follow specific agent criteria (eg, Lemtrada's requirement for prior inadequate response to two or more MS drugs).
• When no step therapy is articulated, include comprehensive prior treatment history to support medical necessity.

Statin plus interferon-beta caution

Statin plus interferon-beta caution: If authorization requests involve combination therapy with high-dose statins and interferon-beta, include documentation of clinical rationale and monitoring because published data suggest potential for increased MRI and clinical disease activity with certain statin-IFN combinations.

• Document clinical justification and monitoring plan when combining statins with IFN-beta therapies.
• Be aware of reported increased MRI/clinical activity with high-dose atorvastatin plus IFN beta-1a.

No explicit authorization or coverage decisions in literature excerpts

No authorization or denial criteria provided in some literature sections: Several background and research summary sections present evidence but do not include operational coverage or denial rules. For authorization decisions, rely on the policy's clinical criteria and coding sections; attach literature only as supporting material.

• Literature citations are supportive — include them but ensure primary clinical documentation meets policy criteria.
• When literature is inconclusive or evidence gaps exist, expect coverage denials for investigational items.